Modality
Multispecific
MOA
RAS(ON)i
Target
KRASG12D
Pathway
NF-κB
SCD
Development Pipeline
Preclinical
~Oct 2018
→ ~Jan 2020
Phase 1
Apr 2020
→ Nov 2025
Phase 1Current
NCT07575755
916 pts·SCD
2020-04→2025-11·Terminated
916 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-11-224mo agoPh2 Data· SCD
Trial Timeline
Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q4
P1/2
Termina…
Catalysts
Ph2 Data
2025-11-22 · 4mo ago
SCD
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07575755 | Phase 1/2 | SCD | Terminated | 916 | LiverFat |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Rilulemzoparlimab | Novartis | Phase 2/3 | KRASG12D | |
| MRK-6781 | Merck & Co | Approved | TIGIT | |
| BMY-2495 | Bristol-Myers Squibb | Phase 3 | KRASG12D | |
| SNY-2934 | Sanofi | Phase 3 | KRASG12D | |
| SNY-9073 | Sanofi | Phase 2 | B7-H3 | |
| Talainavolisib | Novo Nordisk | Preclinical | KRASG12D | |
| GIL-2037 | Gilead Sciences | Approved | KRASG12D | |
| Tixarelsin | Vertex Pharma | Phase 1 | ALK | |
| NBI-408 | Neurocrine | Phase 2/3 | KRASG12D | |
| Fixatuximab | Legend Biotech | Preclinical | CFTR |